Minerva Neurosciences: Q4 Earnings Snapshot
Minerva Neurosciences: Q3 Earnings Snapshot
Minerva Neurosciences: Q2 Earnings Snapshot
In this article, discover how low beta stocks can shimmer in your portfolio!
Minerva Neurosciences: Q1 Earnings Snapshot
Minerva Neurosciences: Q4 Earnings Snapshot
Minerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizophrenia remains in effect.
EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END
/PRNewswire/ -- FinancialNewsMedia.com News Commentary - Anti-anxiety drugs are medications that are used to treat anxiety disorders that are mainly used to...
Minerva Neurosciences: Q3 Earnings Snapshot